VanEck Biotech ETF (NASDAQ:BBH) Stock Price Up 3.2% – What’s Next?

Shares of VanEck Biotech ETF (NASDAQ:BBH) were up 3.2% during mid-day trading on Wednesday . The stock traded as high as $197.20 and last traded at $197.20. Approximately 5,346 shares traded hands during trading, a decline of 22% from the average daily volume of 6,896 shares. The stock had previously closed at $191.10.

VanEck Biotech ETF Stock Up 3.2%

The company has a 50 day moving average of $192.21 and a two-hundred day moving average of $176.57.

VanEck Biotech ETF Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Friday, December 26th. Shareholders of record on Monday, December 22nd were issued a $0.9565 dividend. This represents a yield of 50.0%. The ex-dividend date of this dividend was Monday, December 22nd.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. grew its holdings in shares of VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after buying an additional 48,297 shares in the last quarter. Bleakley Financial Group LLC purchased a new position in shares of VanEck Biotech ETF in the second quarter worth about $2,909,000. Paragon Private Wealth Management LLC boosted its position in VanEck Biotech ETF by 223.5% during the third quarter. Paragon Private Wealth Management LLC now owns 13,394 shares of the company’s stock worth $2,219,000 after acquiring an additional 9,254 shares during the last quarter. Bank of America Corp DE grew its stake in VanEck Biotech ETF by 17.7% during the 2nd quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock valued at $8,042,000 after acquiring an additional 7,898 shares in the last quarter. Finally, Corient Private Wealth LLC grew its stake in VanEck Biotech ETF by 63.5% during the 2nd quarter. Corient Private Wealth LLC now owns 13,290 shares of the company’s stock valued at $2,037,000 after acquiring an additional 5,160 shares in the last quarter. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.